Gain Therapeutics(GANX)
BETHESDA, MDBiotechnology
Focus: Gain Therapeutics is a public biotech company focused on Site-directed Enzyme Enhancement Therapy for neurology and metabolic diseases, operating at early clinical stage with minimal revenue.
Profile data last refreshed 22m ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Total Funding
$300M
Open Jobs
17+2 this month
Stable — net +2 jobs in 30d
4 added, 2 removed. Backfill posture.
Should You Work at Gain Therapeutics?
AI assessmentHigh-risk, high-reward opportunity suitable only for early-stage biotech specialists willing to tolerate significant dilution and cash-burn risk in exchange for potential platform upside.
Why Work Here
- Opportunity to build a platform company from inception—founded in 2023 and newly public (NASDAQ: GANX), offering significant early-stage impact potential.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$55K
Pipeline & Clinical Trials
Envita Stories Methodology in Long-term care Centres for old adults
Long-term Care Centres for Old Adults UsersClinical Trials (1)
NCT06569628Validation of a Life Stories Methodologies in Long-Term Care Centres
N/AHelp build intelligence for Gain Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.